Texas A&M and Celltex Partnering on a Stem Cell-related Alzheimer’s Treatment – Alzheimer’s News Today
Alzheimer’s News Today |
Texas A&M and Celltex Partnering on a Stem Cell-related Alzheimer’s Treatment
Alzheimer’s News Today The fluid-filled sacs, which scientists call vesicles, transport material inside a cell. But cells often release them, and when this happens, they are called exosomes. Researchers at Texas A&M and Celltex plans a multiyear study on whether inflammation … |
Singularity Hub |
Cancer Vaccines May Overhaul Cancer Therapy in the Next Decade
Singularity Hub CAR–T, which genetically enhances a patient’s immune cells to better target cancers, was approved last year to treat certain types of blood cancers. “All of these immunotherapy advances are changing medical practice,” he says. And a tidal wave is … |
UPI.com |
Immunotherapy for peanut allergy safe, effective in clinical trial
UPI.com The idea of using immunotherapy for peanut allergy is not new, as previous research has shown it may be effective. In 2016, the Learning Early About Peanut Allergy trial found infants who consumed 2 grams of peanut protein three times per week led to … AR101 oral immunotherapy effective in reducing severity of peanut allergyHealio Peanut OIT Therapy Sees Success, Boosting Hope for FDA ApprovalAllergic Living Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut …Markets Insider PharmaTimes all 69 news articles » |
Endpoints News |
Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M
Genetic Engineering & Biotechnology News Merck & Co. has agreed to acquire Sydney-based Viralytics for approximately A$502 ($394 million), the companies said today, in a deal that expands the buyer’s immuno-oncology pipeline with a mid-stage oncolytic immunotherapy that has already shown … For Latest Combo, Merck Bets $394M on Viralytics, Cancer-Fighting VirusesXconomy Merck to buy Australian viral immuno-oncology firm for $394 millionReuters.com Merck to buy virus-based cancer drug firm Viralytics for $394 millionReuters Nasdaq –Seeking Alpha all 11 news articles » |